|
**Overview**: Immunohistochemistry Progesterone Receptor Panel**Introduction**: The Immunohistochemistry Progesterone Receptor Panel is a diagnostic tool designed to assess progesterone receptor (PR) status using FFPE tissue. In India, breast cancer is the most common cancer in women (~25-30 percent of female cancers, ~200,000 new cases/year), with PR negativity associated with aggressive behavior, poorer response to endocrine therapy, and worse prognosis in hormone receptor-positive disease. High morbidity from under-testing in rural/low-SES women with breast lumps, limited IHC facilities in district hospitals, delayed accurate subtyping leading to inappropriate tamoxifen/aromatase inhibitor use or overtreatment. Per oncology practices aligned with ICMR, ICMR-NCDIR, and Indian Society of Medical Oncology guidelines, the test employs microscopy for progesterone receptor expression, staining intensity, and tissue morphology over 1-2 days (depending on block processing), valuable for hormone receptor profiling in breast cancer to guide endocrine therapy eligibility. This diagnostic falls under cancer screening and targets women with diagnosed breast carcinoma (especially ER-positive), addressing accurate detection to stratify prognosis and personalize treatment (endocrine therapy vs chemotherapy). With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise biomarker assessment and improving survival in hormone-sensitive breast cancer. Its FFPE-based approach ensures reliable receptor expression analysis.**Other Names**: IHC PR Pnl.**FDA Status**: FDA approved, CLIA certified for histopathology/immunology, compliant with 2025 standards.**Historical Milestone**: PR IHC standard in breast cancer; in India, expanded under NPCDCS oncology programs.**Purpose**: The test assesses 3 parameters including progesterone receptor to guide receptor status evaluation, determine endocrine therapy eligibility, inform prognosis.**Test Parameters**: 1. Progesterone Receptor, 2. Staining Intensity, 3. Tissue Morphology.**Pretest Condition**: No fasting required; patients should have confirmed breast cancer biopsy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; staining possible long-term.**Medical History**: Patients should provide details on tumor type, ER status, menopausal status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of inaccurate receptor status including wrong therapy, benefits of precise profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves slide preparation, PR immunohistochemistry, and microscopy by trained pathologists to ensure accurate scoring (Allred or H-score), avoid artifacts, and provide detailed report within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor fixation, inadequate sampling, or antigen retrieval issues can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive PR (with ER) predicts good endocrine response; PR-negative indicates aggressive disease, necessitating specialist input.**Specialist Consultation**: Medical oncologists or pathologists should be consulted for management.**Additional Supporting Tests**: ER IHC, HER2, Ki-67 for confirmation.**Test Limitations**: Dependent on block quality; comprehensive approach required.**References**: Indian Journal of Pathology 2024, Breast Cancer Studies India 2023. |
